Saxenda Alternatives & Comparison
How Saxenda (liraglutide) compares to Wegovy, Zepbound, Contrave — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Saxenda Alternatives Compared
Once-weekly GLP-1-only injection, generally greater average weight loss than daily liraglutide
Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
Wegovy is the clear successor to Saxenda — both are Novo Nordisk obesity injectables, but the STEP-8 head-to-head trial showed Wegovy 2.4 mg weekly cut body weight 15.8% vs Saxenda 3.0 mg daily at 6.4% over 68 weeks. Wegovy also has the SELECT cardiovascular outcome (MACE -20%) that Saxenda lacks, and a manufacturer cash-pay tier ($349-$499/mo via NovoCare) that Saxenda has no counterpart for. Saxenda retains a narrow role: shorter half-life (~13 hours) makes washout faster for pregnancy planning, and it remains covered by some plans that exclude Wegovy.
Full Wegovy vs Saxenda comparison →Once-weekly dual GIP/GLP-1 injection with the highest average weight loss studied to date
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
Zepbound is the better choice for most adults seeking weight loss: SURMOUNT-1 showed 20.9% body-weight reduction at 72 weeks vs Saxenda's roughly 8% in SCALE Obesity — a nearly 3x gap — and Zepbound dosing is once weekly rather than once daily. Saxenda retains two real niches: it is FDA-approved for adolescents 12 and older (Zepbound is adult-only), and its 1-day washout suits patients planning pregnancy in the near term, vs Zepbound's roughly 6-day washout. Cash access also favors Zepbound at $349-499 via LillyDirect; Saxenda has no manufacturer cash-pay program and runs around $1,400/month retail.
Full Zepbound vs Saxenda comparison →Non-GLP-1 oral option for patients who prefer to avoid injections entirely
Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect.
Contrave's FDA approval was supported by four pivotal 56-week phase 3 trials in the Contrave Obesity Research (COR) program.
Non-GLP-1 oral combination, another injection-free alternative
Qsymia combines two mechanisms in a single capsule.
In the pivotal EQUIP trial (Allison et al.
Compare compounded Semaglutide providers
Compounded semaglutide runs a median of $195/month across 519 vetted-provider price points (range $59–$1,585). Featured partners below, ranked by our partner-economics ordering.
Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $249/month across 473 vetted-provider price points (range $69–$1,400). Featured partners below, ranked by our partner-economics ordering.
Compare every Saxenda provider
See current pricing, verification status, form, and states served across every vetted provider in one place.